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Summary It is considered that percutaneous cardiopulmonary support (PCPS)-
associated thrombosis is rare on antithrombotic coated PCPS if anticoagulation
therapy is appropriately performed. We experienced two cases in which the asso-Shock;
Assisted circulation
ciation between antithrombotic coated PCPS and venous thrombus formation was
highly suspected. These cases suggest that PCPS-associated venous thrombus for-
mation should be checked frequently during and after PCPS even if anticoagulation
was appropriately performed.
© 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
l
t
i
t
areserved.
Percutaneous cardiopulmonary support (PCPS) sys-
tem offers temporary but full cardiopulmonary
support and oxygenation of venous blood. PCPS is
sometimes considered the treatment of choice in
severe conditions including fulminant myocarditis,
pulmonary embolism, and severe acute myocar-
dial infarction [1—7]. Even though PCPS has been
shown to be extremely effective for temporary
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doi:10.1016/j.jjcc.2009.03.002ife support, several possible complications include
hrombosis, hemorrhage, ischemia in lower extrem-
ties, infection, and hemolysis [8,9]. To reduce
he risk of thrombosis associated with PCPS, an
ntithrombotic coating for PCPS had been devel-
ped with several observational studies supporting
his innovation [10,11]. However, the association
etween antithrombotic coated PCPS and venous
hrombus formation has not been fully investigated.
e present two cases in which the association
etween PCPS and venous thrombus formation was
ighly suspected.
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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Fiant thrombus during PCPS
ase report
ase 1
23-year-old man was diagnosed with fulminant
yocarditis, and transferred to our medical center
n August 2006. As his cardiac function deteriorated
ven with high-dose catecholamine and intra-aortic
alloon pumping (IABP) support, PCPS (heparin-
oated CapioxTM system, Terumo Co., Ltd., Tokyo,
apan) was initiated to address circulatory collapse
n the second day. An arterial cannula was inserted
rom the right femoral artery to the right common
liac artery. A venous cannula was inserted from the
ight femoral vein to the right atrium. Initial PCPS
ow was maintained at more than 3.5 L/min. Dur-
ng PCPS, he received anticoagulation therapy of
nfractionated heparin 20,000 unit/day. The acti-
ated partial thromboplastin time (APTT) was kept
t twice the control value (from 62 to 85.5 s). As
he cardiac function had begun to recover gradu-
lly, PCPS was removed without protamine on the
ixth day. We did not detect any thrombus attached
o the arterial and venous cannulas. Two hours
fter removing the PCPS without protamine, a large
hrombus in the inferior vena cava (IVC) was found
y ultrasonography (Fig. 1). The same anticoagu-
ation by unfractionated heparin was continued all
he time. We performed daily ultrasonography dur-
ng PCPS management and routinely checked IVC
y ultrasonography. While the venous thrombus was
ot visible before removing the PCPS, it was easily
ound 2 h after removing the PCPS.
We inserted a temporary IVC ﬁlter (New House
rotect, Toray, Ltd., Tokyo, Japan) from the right
u
t
r
d
igure 1 Ultrasonography showing the thrombus formed in i491
nternal jugular vein. The top of the ﬁlter was
laced at the hepatic vein level. The anticoag-
lation by unfractionated heparin was continued
ith appropriate APTT control (from 62 to 85.5 s).
fter removing the PCPS, the thrombus disappeared
ith the anticoagulation therapy in 3 days. His
ardiac function recovered gradually without pul-
onary thromboembolism and he was discharged
n the 34th day. He was administered warfarin for
months after discharge. After discontinuing war-
arin, complete evaluation for hypercoagulability
as performed. However, there were no abnormal
alues including cardiolipine antibody, anti CL-beta
GPI antibody, lupus anticoagulant, antithrombin
II, Protein C, and Protein S. Now, he has been well
nd has not developed any thrombotic events for
ore than 1 year.
ase 2
39-year-old woman was diagnosed with fulminant
yocarditis and transferred to our medical center
n September 2008. Due to severe cardiac dysfunc-
ion, PCPS (heparin-coated CapioxTM system) was
nitiated on the ﬁrst day of admission. An arterial
annula was inserted from the right femoral artery
o the right common iliac artery. A venous can-
ula was inserted from the right femoral vein to
he right atrium. Initial PCPS ﬂow was maintained
t more than 3.5 L/min. When the patient was on
CPS, she received anticoagulation therapy with
nfractionated heparin with the APTT kept at twice
he control value. As the cardiac function began to
ecover gradually, PCPS was removed on the eighth
ay. We did not detect any thrombus attached to
nferior vena cava in Case 1. Arrow indicates thrombus.
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sFigure 2 Ultrasonography showing the thrombus formed
the arterial and venous cannulas. Nine hours after
removing the PCPS without protamine, a thrombus
in the IVC was found by ultrasonography (Fig. 2).
In this case, we also performed daily ultrasonogra-
phy during PCPS management and checked the IVC.
However, we were unable to detect any thrombus
before removing the PCPS.
After removing the PCPS, the thrombus dis-
appeared with the anticoagulation therapy in 6
days. A complete evaluation for hypercoagulabil-
ity was performed. There were no abnormal values
including cardiolipine antibody, anti CL-beta 2 GPI
antibody, lupus anticoagulant, antithrombin III, Pro-
tein C, and Protein S.
Discussion
We experienced two cases with large thrombus for-
mation presumably associated with PCPS system
use even under appropriate anticoagulation ther-
apy.
The causal relationship between PCPS and the
large thrombus seems to be strong. First, the
thrombus was found at the IVC immediately after
removing the PCPS cannula. As the venous can-
nula was inserted from the right femoral vein
to the right atrium, it was placed at the IVC.
Furthermore, the thrombus disappeared not by
using speciﬁc thrombolytic treatment such as tis-
sue plasminogen activator, but using unfractionated
heparin. Removing the PCPS cannula itself and the
continuation of anticoagulation were effective for
d
i
pnferior vena cava in Case 2. Arrow indicates thrombus.
hrombus dissolution. Finally, these patients did
ot have any predisposing factors for thrombosis,
xcept for the inﬂammatory state due to myocardi-
is [12].
The PCPS system has been used for criti-
ally ill patients such as those with fulminant
yocarditis, myocardial infarction, and pulmonary
hromboembolism [1—7]. Since thrombosis associ-
ted with the PCPS system had been frequently
xperienced, an antithrombotic PCPS system was
ntroduced into clinical use. After developing such
n antithrombotic PCPS system, there were few
eports about thrombosis associated with the PCPS
ystem. However, our cases suggest that PCPS
annula-associated venous thrombus formation can
appen even when using an antithrombotic PCPS
ystem and appropriate anticoagulation.
Unlike arterial thrombosis, venous thrombosis
an be relatively silent unless it causes pulmonary
hromboembolism. In addition, critically ill patients
hat need PCPS have high mortality reaching up to
alf of the patients [13]. As sudden deterioration of
patient’s condition is common in patients need-
ng PCPS, silent fatal pulmonary thromboembolism
ue to a massive venous thrombus may possibly
e overlooked. In addition, as such critically ill
atients usually need mechanical ventilation, pul-
onary thromboembolism may occur without any
ubjective symptoms.
In these two cases, even though we performed
aily ultrasonographic examination before remov-
ng the catheter, we were unable to detect the
resence of venous thrombus when the PCPS
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[iant thrombus during PCPS
annula was inserted. Possibly due to its large
ore (21Fr), venous PCPS cannula may have hin-
ered thorough ultrasound examination around the
atheter. We may have to consider venous throm-
us formation as a possible complication during
CPS management. Vigorous work up for searching
enous thrombus formation and appropriate pre-
ention for pulmonary thromboembolism might be
eeded.
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